Observations placeholder
Onglyza
Identifier
019810
Type of Spiritual Experience
Number of hallucinations: 13
Background
A description of the experience
Saxagliptin , previously identified as BMS-477118, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. In June 2008, it was announced that Onglyza would be the trade name under which saxagliptin will be marketed
Adverse effects
In 4148 patients studied, 3 adverse reactions were seen higher in saxagliptin vs placebo.
1: Adverse Reactions (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Trials* Reported in ≥ 5% of Patients Treated with ONGLYZA (saxagliptin tablets) 5 mg and More Commonly than in Patients Treated with Placebo
| ONGLYZA 5 mg N=882 | Placebo N=799 | |
|---|---|---|
| Upper respiratory tract infection | 68 (7.7) | 61 (7.6) |
| Urinary tract infection | 60 (6.8) | 49 (6.1) |
| Headache | 57 (6.5) | 47 (5.9 |
On Dec, 30, 2016 4,803 people reported to have side effects when taking Onglyza.
Among them, 13 people (0.27%) have Hallucination
Time on Onglyza when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Onglyza :
| Female | Male | |
| Hallucination | 71.43% | 28.57% |
On Jan, 12, 2016: 2,682 people reported to have side effects when taking Onglyza. Among them, 28 people (1.04%) have Death.